UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Laparoendoscopic single-site surgery (LESS) in gynecology: a multi-institutional evaluation

American journal of obstetrics and gynecology, 2010-11, Vol.203 (5), p.501.e1-501.e6

2010

Volltextzugriff (PDF)

A phase 1 evaluation of the safety and tolerability of niraparib in combination with everolimus in advanced ovarian and breast cancers

Cancer medicine (Malden, MA), 2023-09, Vol.12 (18), p.18654-18665

2023

Volltextzugriff (PDF)

Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial

Trials, 2024-05, Vol.25 (1), p.301-301, Article 301

2024

Volltextzugriff (PDF)

Addressing activation of WNT beta-catenin pathway in diverse landscape of endometrial carcinogenesis

American journal of translational research, 2021-01, Vol.13 (11), p.12168-12180

2021

Volltextzugriff (PDF)

Atlas of Tumor and Tumor Microenvironment Cells of Lymphovascular Space Invasion (LVSI) in High-Grade Serous Endometrial Adenocarcinoma: A Case Study

International journal of molecular sciences, 2024-03, Vol.25 (6), p.3441

2024

Volltextzugriff (PDF)

Tumor-TME Bipartite Landscape of PD-1/PD-L1 in Endometrial Cancers

International journal of molecular sciences, 2023-07, Vol.24 (13), p.11079

2023

Volltextzugriff (PDF)

Characterization and Clinical Relevance of Endometrial CAFs: Correlation between Post-Surgery Event and Resistance to Drugs

International journal of molecular sciences, 2023-03, Vol.24 (7), p.6449

2023

Volltextzugriff (PDF)

Identification and Morphological Characterization of Features of Circulating Cancer-Associated Macrophage-like Cells (CAMLs) in Endometrial Cancers

Cancers, 2022-09, Vol.14 (19), p.4577

2022

Volltextzugriff (PDF)

A Laboratory-Friendly CTC Identification: Comparable Double-Immunocytochemistry with Triple-Immunofluorescence

Cancers, 2022-06, Vol.14 (12), p.2871

2022

Volltextzugriff (PDF)

Patient-Derived Primary Cancer-Associated Fibroblasts Mediate Resistance to Anti-Angiogenic Drug in Ovarian Cancers

Biomedicines, 2023-01, Vol.11 (1), p.112

2023

Volltextzugriff (PDF)

A CAF-Based Two-Cell Hybrid Co-Culture Model to Test Drug Resistance in Endometrial Cancers

Biomedicines, 2023-04, Vol.11 (5), p.1326

2023

Volltextzugriff (PDF)

Final results of a phase 1 evaluation of niraparib and everolimus in advanced ovarian and metastatic breast cancer (303)

Gynecologic oncology, 2022-08, Vol.166, p.S159

2022

Volltextzugriff (PDF)

Management of locally advanced cervical cancer

Current opinion in oncology, 2005-09, Vol.17 (5), p.485-492

2005

Volltextzugriff (PDF)

Patient Reported Outcomes and Final Results of Phase 1 Evaluation of the Safety and Clinical Activity of Sapanisertib in Combination with Serabelisib and Paclitaxel in Patients with Advanced Ovarian, Endometrial, or Breast Cancer (044)

Gynecologic oncology, 2022-08, Vol.166, p.S30-S31

2022

Volltextzugriff (PDF)

Giant cell fibroblastoma of the vulva at the site of a previous fibroepithelial stromal polyp: a case report

Journal of lower genital tract disease, 2007-04, Vol.11 (2), p.112-117

2007

Volltextzugriff (PDF)

Phase I dose escalation study of dual PI3K/mTOR inhibition by Sapanisertib and Serabelisib in combination with paclitaxel in patients with advanced solid tumors

Gynecologic oncology, 2022-09, Vol.166 (3), p.403-409

2022

Volltextzugriff (PDF)

Avera/Sema4 oncology and analytics protocol (ASAP): Quantification of HER2 protein expression and activation status in gynecologic malignancies utilizing reverse-phase protein array (RPPA) (1267)

Gynecologic oncology, 2023-09, Vol.176, p.S169-S170

2023

Volltextzugriff (PDF)

Final results of phase 1 evaluation of the safety and clinical activity of sapanisertib in combination with serabelisib and paclitaxel in patients with advanced ovarian, endometrial, or breast cancer

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.5569-5569

2021

Volltextzugriff (PDF)

Clinical outcomes of gynecologic tumor treatment correlate with ERK protein phosphorylation as measured by a CLIA-accredited phosphoprotein assay

Gynecologic oncology, 2024-11, Vol.190, p.S209-S210

2024

Volltextzugriff (PDF)

Development of a molecular and clinical evidence-based algorithm for selecting optimal precision therapeutic strategy for patients with ovarian carcinoma (157)

Gynecologic oncology, 2022-08, Vol.166, p.S94-S95

2022

Volltextzugriff (PDF)

Abstract 1427: Co-alteration of the nucleosome remodeler, ARID1A with the PI3K-pathway genes: A signaling opportunity in ovarian cancers

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.1427-1427

2020

Volltextzugriff (PDF)

Multi-omic and clinical data analysis of pre-menopausal women under 45 years of age diagnosed with endometrial cancer and enrolled in the ASAP trial (2154)

Gynecologic oncology, 2023-09, Vol.176, p.S229-S230

2023

Volltextzugriff (PDF)

Comprehensive molecular profiling and deep clinical annotation of electronic health records in patients with cancer: Implementation of the Avera/Sema4 oncology and analytics protocol (ASAP) in gynecologic oncology (1255)

Gynecologic oncology, 2023-09, Vol.176, p.S161-S162

2023

Volltextzugriff (PDF)

Open-label, phase 2, randomized controlled multicenter study comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in participants with homologous recombination deficient stage III/IV ovarian cancer: Trial in progress (1252)

Gynecologic oncology, 2023-09, Vol.176, p.S159-S160

2023

Volltextzugriff (PDF)

Clinical and financial outcomes in cancer patients with integration of specialty palliative care versus standard oncology care

Journal of clinical oncology, 2019-09, Vol.37 (27_suppl), p.47-47

2019

Volltextzugriff (PDF)

1 – 25 von 40

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(38)

Publikationsform

Artikel
(39)
Berichte
(1)

Sprache

Englisch
(40)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Laparoendoscopic single-site surgery (LESS) in gynecology: a multi-institutional evaluation

A phase 1 evaluation of the safety and tolerability of niraparib in combination with everolimus in advanced ovarian and breast cancers

Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial

Addressing activation of WNT beta-catenin pathway in diverse landscape of endometrial carcinogenesis

Atlas of Tumor and Tumor Microenvironment Cells of Lymphovascular Space Invasion (LVSI) in High-Grade Serous Endometrial Adenocarcinoma: A Case Study

Tumor-TME Bipartite Landscape of PD-1/PD-L1 in Endometrial Cancers

Characterization and Clinical Relevance of Endometrial CAFs: Correlation between Post-Surgery Event and Resistance to Drugs

Identification and Morphological Characterization of Features of Circulating Cancer-Associated Macrophage-like Cells (CAMLs) in Endometrial Cancers

A Laboratory-Friendly CTC Identification: Comparable Double-Immunocytochemistry with Triple-Immunofluorescence

Patient-Derived Primary Cancer-Associated Fibroblasts Mediate Resistance to Anti-Angiogenic Drug in Ovarian Cancers

A CAF-Based Two-Cell Hybrid Co-Culture Model to Test Drug Resistance in Endometrial Cancers

Final results of a phase 1 evaluation of niraparib and everolimus in advanced ovarian and metastatic breast cancer (303)

Management of locally advanced cervical cancer

Patient Reported Outcomes and Final Results of Phase 1 Evaluation of the Safety and Clinical Activity of Sapanisertib in Combination with Serabelisib and Paclitaxel in Patients with Advanced Ovarian, Endometrial, or Breast Cancer (044)

Giant cell fibroblastoma of the vulva at the site of a previous fibroepithelial stromal polyp: a case report

Phase I dose escalation study of dual PI3K/mTOR inhibition by Sapanisertib and Serabelisib in combination with paclitaxel in patients with advanced solid tumors

Avera/Sema4 oncology and analytics protocol (ASAP): Quantification of HER2 protein expression and activation status in gynecologic malignancies utilizing reverse-phase protein array (RPPA) (1267)

Final results of phase 1 evaluation of the safety and clinical activity of sapanisertib in combination with serabelisib and paclitaxel in patients with advanced ovarian, endometrial, or breast cancer

Clinical outcomes of gynecologic tumor treatment correlate with ERK protein phosphorylation as measured by a CLIA-accredited phosphoprotein assay

Development of a molecular and clinical evidence-based algorithm for selecting optimal precision therapeutic strategy for patients with ovarian carcinoma (157)

Abstract 1427: Co-alteration of the nucleosome remodeler, ARID1A with the PI3K-pathway genes: A signaling opportunity in ovarian cancers

Multi-omic and clinical data analysis of pre-menopausal women under 45 years of age diagnosed with endometrial cancer and enrolled in the ASAP trial (2154)

Comprehensive molecular profiling and deep clinical annotation of electronic health records in patients with cancer: Implementation of the Avera/Sema4 oncology and analytics protocol (ASAP) in gynecologic oncology (1255)

Open-label, phase 2, randomized controlled multicenter study comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in participants with homologous recombination deficient stage III/IV ovarian cancer: Trial in progress (1252)

Clinical and financial outcomes in cancer patients with integration of specialty palliative care versus standard oncology care

Suchergebnisse filtern